Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333862
| Line item | For the six monthsended June 30, 2026 | For the six monthsended June 30, 2025 |
|---|---|---|
| Purchases of short-term investments | (70,044) | (56,093) |
| Sale of short-term investments | 10,075 | - |
| Maturities of short-term investments | 123,481 | 100,033 |
| Purchases of property and equipment | (164) | (313) |
| Proceeds from sales of equipment | 193 | - |
| Net cash provided by investing activities | 63,541 | 43,627 |
| Cash flows from financing activities | ||
| Payment of deferred offering costs | (454) | (63) |
Item 1. Financial Statements.
FAQ
- What is Rapport Therapeutics, Inc.'s capex?
- Rapport Therapeutics, Inc. (RAPP) reported capex of $78K in Q2 2026.
- How has Rapport Therapeutics, Inc.'s capex changed year-over-year?
- Rapport Therapeutics, Inc.'s capex increased by 254.5% year-over-year, from $22K to $78K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Rapport Therapeutics, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude